☆ 4.6 Article

Case Report: Should Regorafenib be prescribed as a continuous schedule in gastrointestinal stromal tumors? Three case reports on Regorafenib personalized schedule

FRONTIERS IN ONCOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Article Oncology

Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up

P. G. Casali et al.

ANNALS OF ONCOLOGY (2022)

添加到收藏夹

Article Chemistry, Medicinal

Population Pharmacokinetic Analysis of Pazopanib in Patients and Determination of Target AUC

Agustos Cetin Ozbey et al.

Summary: Pazopanib is a potent kinase inhibitor approved for advanced renal cell carcinoma and soft tissue sarcoma. Its pharmacokinetics show significant variability. By constructing concentration-time profiles, a target area under the curve (AUC) can be determined for optimal efficacy and minimal side effects.

PHARMACEUTICALS (2021)

添加到收藏夹

Review Biochemistry & Molecular Biology

Gastrointestinal Stromal Tumors (GISTs): Novel Therapeutic Strategies with Immunotherapy and Small Molecules

Christos Vallilas et al.

Summary: Gastrointestinal stromal tumors (GISTs) are the most common types of malignant mesenchymal tumors in the gastrointestinal tract, with treatment options including drugs and immunotherapy, some patients have gene mutations, and drug resistance is becoming more common.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

添加到收藏夹

Article Medicine, General & Internal

Gastrointestinal stromal tumours

Jean-Yves Blay et al.

Summary: Gastrointestinal stromal tumours (GIST) are rare malignancies with 80% of cases having KIT or PDGFRA activating mutations. Localized GIST can be cured through surgery, while advanced resistant GIST with resistance mutations require treatment with new drugs.

NATURE REVIEWS DISEASE PRIMERS (2021)

添加到收藏夹

Review Oncology

The Anti-VEGF(R) Drug Discovery Legacy: Improving Attrition Rates by Breaking the Vicious Cycle of Angiogenesis in Cancer

Domenico Ribatti et al.

Summary: Several anti-angiogenic drugs are approved for cancer treatment, but resistance and adverse effects may occur. Combining multiple anti-angiogenic molecules or using them in combination with other treatment regimens is indicated as alternative therapeutic strategies to overcome resistance. Comprehensive omics profiling is crucial for increasing clinical benefits and overcoming resistance to anti-angiogenic therapies.

CANCERS (2021)

添加到收藏夹

Article Oncology

Standard versus personalized schedule of regorafenib in metastatic gastrointestinal stromal tumors: a retrospective, multicenter, real-world study

M. Nannini et al.

Summary: The study investigated the efficacy and safety of personalized schedules of regorafenib in patients with metastatic GIST compared to the standard schedule, showing that personalized schedules were associated with a significant improvement in therapeutic outcomes. This suggests that optimizing regorafenib treatment in GIST patients may be the best strategy for maximizing long-term therapy.

ESMO OPEN (2021)

添加到收藏夹

Review Oncology

Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis

Alessandro Rizzo et al.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2020)

添加到收藏夹

Review Gastroenterology & Hepatology

Gastrointestinal stromal tumor: epidemiology, diagnosis, and treatment

George Mantese

CURRENT OPINION IN GASTROENTEROLOGY (2019)

添加到收藏夹

Article Oncology

Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of lmatinib and Sunitinib: A Multicenter Study Based on the Management Access Program

Myoung Kyun Son et al.

CANCER RESEARCH AND TREATMENT (2017)

添加到收藏夹

Article Oncology

Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice

Margherita Nannini et al.

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2017)

添加到收藏夹

Article Oncology

Phase I dose-escalation study of continuously administered regorafenib (BAY 73-4506), an inhibitor of oncogenic and angiogenic kinases, in patients with advanced solid tumors.

T. Shimizu et al.

JOURNAL OF CLINICAL ONCOLOGY (2017)

添加到收藏夹

Article Multidisciplinary Sciences

Treatment patterns, efficacy and toxicity of regorafenib in gastrointestinal stromal tumour patients

Gustavo Schvartsman et al.

SCIENTIFIC REPORTS (2017)

添加到收藏夹

Article Oncology

Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies

Kjetil Soreide et al.

CANCER EPIDEMIOLOGY (2016)

添加到收藏夹

Article Oncology

Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life setting

Stephane Bouchet et al.

EUROPEAN JOURNAL OF CANCER (2016)

添加到收藏夹

Article Medicine, General & Internal

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

George D. Demetri et al.

LANCET (2013)

添加到收藏夹

Article Medicine, General & Internal

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

Axel Grothey et al.

LANCET (2013)

添加到收藏夹

Article Oncology

Optimizing Tyrosine Kinase Inhibitor Therapy in Gastrointestinal Stromal Tumors: Exploring the Benefits of Continuous Kinase Suppression

Axel Le Cesne et al.

ONCOLOGIST (2013)

添加到收藏夹

Review Oncology

Adjuvant treatment of GIST: patient selection and treatment strategies

Heikki Joensuu

NATURE REVIEWS CLINICAL ONCOLOGY (2012)

添加到收藏夹

Article Oncology

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure

S. George et al.

EUROPEAN JOURNAL OF CANCER (2009)

添加到收藏夹

Article Oncology

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. A. Eisenhauer et al.

EUROPEAN JOURNAL OF CANCER (2009)

添加到收藏夹

Article Oncology

Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis

Jason S. Gold et al.

LANCET ONCOLOGY (2009)

添加到收藏夹

Article Medicine, General & Internal

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

George D. Demetri et al.

LANCET (2006)

添加到收藏夹

Article Medicine, Research & Experimental

Rapid vascular regrowth in tumors after reversal of VEGF inhibition

Michael R. Mancuso et al.

JOURNAL OF CLINICAL INVESTIGATION (2006)

添加到收藏夹

Article Medical Laboratory Technology

Gastrointestinal stromal tumors: Pathology and prognosis at different sites

Markku Miettinen et al.

SEMINARS IN DIAGNOSTIC PATHOLOGY (2006)

添加到收藏夹

Article Medicine, General & Internal

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

GD Demetri et al.

NEW ENGLAND JOURNAL OF MEDICINE (2002)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.